Rosenpark Research GmbH
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases
At Rosenpark Research GmbH in Darmstadt, much of the trial activity centers on skin and connective tissue diseases, especially atopic dermatitis, psoriasis, prurigo nodularis, hidradenitis suppurativa, and vitiligo. The studies are mainly designed to test new therapies, measure symptom relief, and assess long-term safety and tolerability.
- Testing new treatments for moderate-to-severe atopic dermatitis and related itch symptoms
- Evaluating therapies for psoriasis and plaque psoriasis, including skin clearance and disease control
- Studying options for prurigo nodularis to improve itch and skin lesions
- Assessing treatment effectiveness in hidradenitis suppurativa and long-term symptom management
- Exploring approaches for vitiligo and repigmentation outcomes
The site’s dermatology-focused portfolio reflects a strong interest in both short-term improvement and ongoing safety across chronic inflammatory skin conditions.
Immune System Diseases
Another major research area is immune system diseases, with clinical trials examining conditions such as chronic spontaneous urticaria, cold-induced urticaria, and symptomatic dermographism. These studies aim to better control immune-driven skin reactions and improve daily quality of life for affected patients.
- Evaluating new therapies for chronic spontaneous urticaria
- Studying treatments for cold-induced urticaria and symptomatic dermographism
- Measuring reductions in hives activity and provocation-related symptoms
- Assessing safety and durability of response in immune-related skin disorders
These trials focus on whether investigational treatments can reduce flare-ups, ease discomfort, and provide more consistent symptom control over time.
Hormonal Diseases
The site also supports research in hormonal diseases, including studies on female androgenetic alopecia. This work is aimed at understanding hair loss linked to hormonal imbalance and testing treatments that may help restore hair growth.
- Investigating therapies for female androgenetic alopecia
- Measuring changes in hair count and visible hair density
- Comparing treatment effectiveness against placebo or standard care
At this laboratory and research facility, hair-loss studies add a distinct endocrine-related dimension to an otherwise dermatology-heavy portfolio.
Physical Phenomena
Research under physical phenomena includes trials that evaluate visible facial lines and wrinkles, such as glabellar lines and upper facial lines. These studies are designed to assess whether new treatments can improve appearance and patient satisfaction in aesthetic medicine.
- Testing treatments for moderate to severe glabellar lines
- Evaluating therapies for upper facial lines and related wrinkle concerns
- Assessing appearance improvement and tolerability
- Comparing results with placebo to determine treatment benefit
This area broadens the site’s clinical research beyond disease management into the study of visible skin changes and aesthetic outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Celldex Therapeutics Inc.2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rosenpark Research GmbH
lock Showing 1 of 33 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Barzolvolimab | 3 | Unknown | 2024-12-16 | 2026-04-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.